[go: up one dir, main page]

NO982185L - Novel macrocyclic compounds as metalloproteinase inhibitors - Google Patents

Novel macrocyclic compounds as metalloproteinase inhibitors

Info

Publication number
NO982185L
NO982185L NO982185A NO982185A NO982185L NO 982185 L NO982185 L NO 982185L NO 982185 A NO982185 A NO 982185A NO 982185 A NO982185 A NO 982185A NO 982185 L NO982185 L NO 982185L
Authority
NO
Norway
Prior art keywords
compounds
metalloproteinase inhibitors
macrocyclic compounds
inhibitors
novel macrocyclic
Prior art date
Application number
NO982185A
Other languages
Norwegian (no)
Other versions
NO982185D0 (en
Inventor
Chu-Biao Xue
Robert Joseph Cherney
Carl Peter Decicco
William Frank Degrado
Xiaohua He
Carl Nicolas Hodge
Irina Cipora Jacobson
Ronald Louis Magolda
Elizabeth Catherine Arner
Jingwu Duan
David J Nelson
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO982185D0 publication Critical patent/NO982185D0/en
Publication of NO982185L publication Critical patent/NO982185L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Denne oppfinnelsen vedrører makro- sykliske molekyler som inhiberer metalloproteinaser, inkludert aggrekanase, og produksjonen av tumornekrosefaktor (TNF). Særlig er forbindelsene inhibitorer for metalloproteinaser som er involvert i vevs- nedbrytning, og inhibitorer for frigjørelsen av tumornekrosefaktor. Fore- liggende oppfinnelse vedrører også farmasøytiske preparater som omfatter slike forbindelser, og fremgangsmåter for anvendelse av disse forbindelsene til behandling av inflammatoriske syk- dommer.This invention relates to macrocyclic molecules that inhibit metalloproteinases, including aggregate kinase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of tumor necrosis factor release. The present invention also relates to pharmaceutical compositions comprising such compounds, and methods of using these compounds for the treatment of inflammatory diseases.

NO982185A 1995-11-14 1998-05-13 Novel macrocyclic compounds as metalloproteinase inhibitors NO982185L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US668495P 1995-11-14 1995-11-14
US64690296A 1996-05-08 1996-05-08
US74343996A 1996-11-01 1996-11-01
PCT/US1996/018382 WO1997018207A2 (en) 1995-11-14 1996-11-13 Novel macrocyclic compounds as metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
NO982185D0 NO982185D0 (en) 1998-05-13
NO982185L true NO982185L (en) 1998-07-13

Family

ID=27358171

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982185A NO982185L (en) 1995-11-14 1998-05-13 Novel macrocyclic compounds as metalloproteinase inhibitors

Country Status (17)

Country Link
EP (1) EP0863885A2 (en)
JP (1) JP2000502050A (en)
CN (1) CN1202161A (en)
BR (1) BR9611563A (en)
CA (1) CA2237524A1 (en)
CZ (1) CZ144798A3 (en)
EE (1) EE9800115A (en)
HR (1) HRP960533A2 (en)
HU (1) HUP0201479A2 (en)
IL (1) IL124366A0 (en)
LV (1) LV12167B (en)
MX (1) MX9803851A (en)
NO (1) NO982185L (en)
PL (1) PL326714A1 (en)
SI (1) SI9620120A (en)
SK (1) SK63498A3 (en)
WO (1) WO1997018207A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9820B (en) * 1997-01-07 1998-07-02 Abbott Lab Macrocyclic inhibitors of matrix metalloproteinases and tnf x secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
EE200000574A (en) 1998-03-31 2002-10-15 Dupont Pharmaceuticals Company Pharmaceutical compounds for displaying angiogenic disorders
EP1084113A1 (en) * 1998-06-11 2001-03-21 Du Pont Pharmaceuticals Company A process for the preparation of macrocyclic metalloprotease inhibitors
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6649377B1 (en) 1999-05-10 2003-11-18 Syntex (U.S.A.) Llc Human aggrecanase and nucleic acid compositions encoding the same
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
MXPA02000862A (en) 2000-06-01 2003-07-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abgr; PROTEIN PRODUCTION.
EP2087908B1 (en) 2001-06-26 2018-05-30 Amgen Inc. Antibodies to opgl
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005044780A1 (en) * 2003-11-10 2005-05-19 Kyorin Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative, addition salt thereof, and s1p receptor control agent
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
EP2429290B1 (en) 2009-05-11 2014-01-01 Purdue Research Foundation Compounds and methods for treating aids and hiv infections
EP2710018B8 (en) * 2011-05-19 2022-02-23 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
CN102276546B (en) * 2011-05-31 2014-06-25 中国科学院广州生物医药与健康研究院 Compounds useful as proteoglycanase modulators and uses thereof
CN106432126B (en) * 2016-09-18 2018-12-28 广西师范大学 1-Oxygen-2,8-diazacyclononane derivative and its synthesis method
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis

Also Published As

Publication number Publication date
PL326714A1 (en) 1998-10-26
HRP960533A2 (en) 1998-04-30
BR9611563A (en) 1999-03-02
MX9803851A (en) 1998-09-30
JP2000502050A (en) 2000-02-22
WO1997018207A3 (en) 1997-07-24
EP0863885A2 (en) 1998-09-16
SI9620120A (en) 1999-06-30
LV12167A (en) 1998-11-20
CN1202161A (en) 1998-12-16
SK63498A3 (en) 1999-01-11
NO982185D0 (en) 1998-05-13
CA2237524A1 (en) 1997-05-22
WO1997018207A2 (en) 1997-05-22
LV12167B (en) 1999-03-20
EE9800115A (en) 1998-10-15
CZ144798A3 (en) 1998-10-14
IL124366A0 (en) 1998-12-06
HUP0201479A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
NO982185L (en) Novel macrocyclic compounds as metalloproteinase inhibitors
NO20000784L (en) Novel aggrecanase inhibitors and matrix metalloproteinases for the treatment of arthritis
FI961976A0 (en) Peptidyl compounds and their therapeutic use as metalloproteinase inhibitors
NO20055863L (en) W-carboxyaryl-substituted diphenylurea compounds as raf kinase inhibitors
EA200200768A1 (en) INDAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MODULATION OR INHIBITION OF CELLULAR PROLIFERATION
UA48939C2 (en) Disubstituted furanons, methods for synthesis, pharmaceutical composition, method for treating inflammatory disease, intermediate substances
BR9916930A (en) Aromatic heterocyclic compounds as anti-inflammatory agents
MXPA04002070A (en) Substituted indazole compounds for the treatment of inflammation.
FI973087A7 (en) Cell adhesion inhibitors
AU2003209118A1 (en) Aryl ureas as kinase inhibitors
NO326660B1 (en) Imidazolyl-cyclic acetal compounds, pharmaceutical compositions containing these compounds and use of the compounds
NO20052595L (en) Compositions useful as inhibitors of ROCK and other protein kinases.
EA200501676A1 (en) PHOSPHONATE-CONTAINING KINASE INHIBITORS (OPTIONS), METHOD FOR THEIR RECEIVING, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM ON THEIR BASIS AND METHOD FOR INHIBING KINASE IN MOLOPYTIC TREATMENT THEM
MXPA05010958A (en) Indazole derivatives as jnk inhibitors.
NO20054769L (en) Substituted phenylalkanoic acids
UA39166C2 (en) DERIVATIVES OF N-HYDROXYROURE, WHICH ARE INHIBITORS OF LIPOXYGENASE IN MAMMALS, THE METHOD OF OBTAINING THEM AND THE METHOD OF INHIBITING LIPOXYGENASE IN MAMMALS
NO20052888L (en) Diamin triazoles useful as inhibitors of protein kinases
SE9800836D0 (en) New Compounds
DE602004003806D1 (en) 1- (2H-PYRAZOL-3-YL) -3-ä4-Ä1- (BENZOYL) -PIPERIDIN-4-YLMETHYLÜ-PHENYLU-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE P38 KINASE AND / OR TNF FOR THE TREATMENT OF INFLAMMATION
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors
ATE329909T1 (en) 1,2,3-TRIAZOLAMIDE DERIVATIVES AS CYTOKIN INHIBITORS
EA200401319A1 (en) NEW HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR USE IN MEDICINE
EE9800230A (en) Diphenylstilbenes as prodrugs of COX-2 inhibitors
NO975503L (en) 4,4- (Disubstituted) Cyclohexan-1-oler Monomers and Related Compounds
EA199800372A1 (en) NEW MICROCYCLIC COMPOUNDS INHIBITORS